Artiva Biotherapeutics is implementing a wind-down of its operations, including the discontinuation of its AlloNK cell therapy candidate and a 94% reduction in workforce. The company estimates it will incur $27 million to $35 million in total charges, including up to $15 million for clinical trial close-out and up to $20 million for severance and termination costs. The workforce reduction is expected to be completed in the first quarter of 2027 as the company explores strategic alternatives.
Artiva Biotherapeutics is undergoing a significant strategic shift, including the wind-down of its AlloNK development program and a workforce reduction to preserve capital. The company is currently evaluating strategic alternatives to maximize stockholder value while managing its remaining clinical close-out and intellectual property activities.
Artiva Biotherapeutics Chief Tech Operations Officer Christopher Horan Sells $43.6K of Stock
Christopher Horan, Chief Tech Operations Officer, sold 10,423 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $43.6K in total on Nov 2, 2026. Shares held after the trade: 302,321 (-3.3%).
Artiva Biotherapeutics COO, CLO, Compliance Officer Jennifer Bush Sells $35.3K of Stock
Jennifer Bush, COO, CLO, Compliance Officer, sold 8,439 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $35.3K in total on Nov 2, 2026. Shares held after the trade: 357,720 (-2.3%).
Artiva Biotherapeutics CEO Fred Aslan Sells $260K of Stock
Fred Aslan, CEO, sold 62,178 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $260K in total on Nov 2, 2026. Shares held after the trade: 1,457,428 (-4.1%).
Artiva Biotherapeutics is halting all development of its lead cell therapy candidate AlloNK (AB-101) and implementing a 94% workforce reduction after clinical data failed to meet durability thresholds and two patient deaths occurred. The company has engaged Leerink Partners to explore strategic alternatives, including a potential merger, sale, or liquidation, while reporting a preliminary cash balance of $319.1 million.
Artiva Biotherapeutics CEO Fred Aslan Sells $169K of Stock
Fred Aslan, CEO, sold 23,463 shares of Artiva Biotherapeutics, Inc. at $7.20 a share, worth $169K in total on Oct 6, 2026. Shares held after the trade: 1,519,606 (-1.5%).
Artiva Biotherapeutics Chief Tech Operations Officer Christopher Horan Sells $70.7K of Stock
Christopher Horan, Chief Tech Operations Officer, sold 10,340 shares of Artiva Biotherapeutics, Inc. at $6.84 a share, worth $70.7K in total on Oct 5, 2026. Shares held after the trade: 312,744 (-3.2%).
Artiva Biotherapeutics COO, CLO, Compliance Officer Jennifer Bush Sells $57.2K of Stock
Jennifer Bush, COO, CLO, Compliance Officer, sold 8,370 shares of Artiva Biotherapeutics, Inc. at $6.84 a share, worth $57.2K in total on Oct 5, 2026. Shares held after the trade: 366,159 (-2.2%).
Artiva Biotherapeutics CEO Fred Aslan Sells $422K of Stock
Fred Aslan, CEO, sold 61,696 shares of Artiva Biotherapeutics, Inc. at $6.84 a share, worth $422K in total on Oct 5, 2026. Shares held after the trade: 1,543,069 (-3.8%).